Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (111-120 of 314) with videos related to

Pageof 32
Sort By:
Journal of the American Academy of Dermatology|January 19, 2016
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adultsEric L Simpson, Thomas Bieber, Laurent Eckert, et al.
The Journal of Investigative Dermatology|November 17, 2007
Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigenErin G Harper, Eric L Simpson, Rodd H Takiguchi, et al.
Allergy|July 17, 2023
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibitionEric L Simpson, Emma Guttman-Yassky, Lawrence F Eichenfield, et al.
The Journal of Investigative Dermatology|September 5, 2014
The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatologyJochen Schmitt, Christian Apfelbacher, Phyllis I Spuls, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 31, 2026
Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trialsAndreas Wollenberg, Eric L Simpson, Yael A Leshem, et al.
Frontiers in Immunology|June 22, 2026
Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammationEric L Simpson, Oscar Palomares, Brian S Kim, et al.
Plos One|March 1, 2018
Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitisMartin Glatz, Jay-Hyun Jo, Elizabeth A Kennedy, et al.
Dermatology and Therapy|May 28, 2021
Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, Ashish Bansal, et al.
American Journal of Clinical Dermatology|October 7, 2023
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1Eric L Simpson, Andrew Blauvelt, Jonathan I Silverberg, et al.
Dermatology Online Journal|September 7, 2004
Tacrolimus ointment: utilization patterns in children under age 2 yearsTamara Salam Housman, Amy B Norton, Steven R Feldman, et al.
Pageof 32

Showing results (111-120 of 314) with videos related to

Sort By:
Pageof 32
Journal of the American Academy of Dermatology|January 19, 2016
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adultsEric L Simpson, Thomas Bieber, Laurent Eckert, et al.
The Journal of Investigative Dermatology|November 17, 2007
Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigenErin G Harper, Eric L Simpson, Rodd H Takiguchi, et al.
Allergy|July 17, 2023
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibitionEric L Simpson, Emma Guttman-Yassky, Lawrence F Eichenfield, et al.
The Journal of Investigative Dermatology|September 5, 2014
The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatologyJochen Schmitt, Christian Apfelbacher, Phyllis I Spuls, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 31, 2026
Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trialsAndreas Wollenberg, Eric L Simpson, Yael A Leshem, et al.
Frontiers in Immunology|June 22, 2026
Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammationEric L Simpson, Oscar Palomares, Brian S Kim, et al.
Plos One|March 1, 2018
Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitisMartin Glatz, Jay-Hyun Jo, Elizabeth A Kennedy, et al.
Dermatology and Therapy|May 28, 2021
Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, Ashish Bansal, et al.
American Journal of Clinical Dermatology|October 7, 2023
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1Eric L Simpson, Andrew Blauvelt, Jonathan I Silverberg, et al.
Dermatology Online Journal|September 7, 2004
Tacrolimus ointment: utilization patterns in children under age 2 yearsTamara Salam Housman, Amy B Norton, Steven R Feldman, et al.
Pageof 32